| 形态 | Liquid |
|---|
| 宿主种属 | Humanized |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | IgG1-kappa |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 3.33mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | FGF-inducible 14, TNFRSF12A, FN14, CD266, TweakR, Fibroblast growth factor-inducible immediate-early response protein 14, Tweak-receptor, Tumor necrosis factor receptor superfamily member 12A |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | Q9NP84 |
|---|
| 背景信息 | Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .<br>• TWEAK/Fn14 signaling in tumors., PMID:28639899<br/>• The TWEAK/Fn14/CD163 axis-implications for metabolic disease., PMID:34542797<br/>• TWEAK/Fn14 axis in respiratory diseases., PMID:32526219<br/>• TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer., PMID:38965263<br/>• Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges., PMID:32053869<br/>• Role of the TWEAK/Fn14 pathway in autoimmune diseases., PMID:26659091<br/>• TWEAK/Fn14 signaling: a promising target in intervertebral disc degeneration., PMID:26907852<br/>• Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration., PMID:32200423<br/>• Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in rheumatic diseases., PMID:23106895<br/>• Tumor Necrosis Factor Receptor Mediates Fibroblast Growth Factor-Inducible 14 Signaling., PMID:28934756<br/> |
|---|
| 别名 | PDL192, 1062149-33-0 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|